The participating health insurance companies pursue the goal of concluding discount agreements with all suitable pharmaceutical companies in accordance with Section 130c (1) SGB V for the active ingredient ponesimod. The contract is concluded within the framework of the open-house originals procedure of the health insurance companies:

Individual negotiations on the contents of the contract are not conducted, uniform conditions apply. The health insurance companies do not guarantee exclusivity to individual contractual partners. The contract period is a maximum of 24 months starting on 01.11.2023. The contract ends no later than 31.10.2025, regardless of the date of conclusion of the contract. If the patent expires before the above-mentioned end date, the contract ends automatically at the end of the month in which the patent expires. All further information can be found in the participation and contract documents.

It is possible to join this open house originals procedure at any time within the contract period.

Due to the existence of industrial property rights with regard to the active ingredient or combination of active ingredients that is the subject of the contract, the participation and contract documents are only made available to pharmaceutical companies who offer/place medicinal products on the active ingredient or combination of active ingredients subject to the proceedings or who credibly demonstrate to TK that such medicinal products are available within the to want to offer/place on the market the term of the contract.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This notice does not concern the award of a public contract within the meaning of the Public Procurement Directive (2014/24/EC) or antitrust law. In order to provide the broadest possible information to interested pharmaceutical companies, this notice is made in the

Supplement to the Official Journal of the European Union. The procedural designation "Open procedure" used in the context of this notice text in accordance with Section IV.1.1) and the indication of the award criteria in accordance with Section II.2.5) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not imply any submission to public procurement regulations, the validity of which is not mandatory by law or procurement regulations.